» Articles » PMID: 38255226

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization

Overview
Journal Biomedicines
Date 2024 Jan 23
PMID 38255226
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are short, non-coding ribonucleic acids (RNAs) associated with gene expression regulation. Since the discovery of the first miRNA in 1993, thousands of miRNAs have been studied and they have been associated not only with physiological processes, but also with various diseases such as cancer and inflammatory conditions. MiRNAs have proven to be not only significant biomarkers but also an interesting therapeutic target in various diseases, including cancer. In acute myeloid leukemia (AML), miRNAs have been regarded as a welcome addition to the limited therapeutic armamentarium, and there is a vast amount of data on miRNAs and their dysregulation. Macrophages are innate immune cells, present in various tissues involved in both tissue repair and phagocytosis. Based on their polarization, macrophages can be classified into two groups: M1 macrophages with pro-inflammatory functions and M2 macrophages with an anti-inflammatory action. In cancer, M2 macrophages are associated with tumor evasion, metastasis, and a poor outcome. Several miRNAs have been associated with a poor prognosis in AML and with either the M1 or M2 macrophage phenotype. In the present paper, we review miRNAs with a reported negative prognostic significance in cancer with a focus on AML and analyze their potential impact on macrophage polarization.

Citing Articles

Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.

Vlahopoulos S, Varisli L, Zoumpourlis P, Spandidos D, Zoumpourlis V Int J Oncol. 2024; 65(6).

PMID: 39513593 PMC: 11575927. DOI: 10.3892/ijo.2024.5703.

References
1.
Li Z, Chen P, Su R, Li Y, Hu C, Wang Y . Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015; 126(17):2005-15. PMC: 4616234. DOI: 10.1182/blood-2015-04-639062. View

2.
Wang N, Tan H, Feng Y, Zhang C, Chen F, Feng Y . microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance. Cancers (Basel). 2018; 11(1). PMC: 6356664. DOI: 10.3390/cancers11010007. View

3.
Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

4.
Cencic R, Carrier M, Trnkus A, Porco Jr J, Minden M, Pelletier J . Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2009; 34(4):535-41. PMC: 4117193. DOI: 10.1016/j.leukres.2009.07.043. View

5.
Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S . MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012; 26(9):2011-8. DOI: 10.1038/leu.2012.90. View